DARE (STOCKS)
Dare Bioscience, Inc. Common Stock
$0.899900
-0.470100 (-34.31%)
Prev close: $1.370000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals Major
- CEO
- Sabrina Martucci Johnson, MBA
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $13.65M
- Employees
- 23
- P/E (TTM)
- -1.18
- P/B (TTM)
- -25.16
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.20 | $-0.30 | +0.0958 | +32.39% |
|
Dec 2025 (Q4)
|
$-0.02 | $-0.44 | +0.4212 | +95.47% |
|
Sep 2025 (Q3)
|
$-0.28 | $-0.36 | +0.0838 | +23.03% |
|
Jun 2025 (Q2)
|
$-0.45 | $-0.59 | +0.1416 | +23.94% |
Financial Statements
| Revenues | $1.37M |
| Benefits Costs and Expenses | $14.57M |
| Cost Of Revenue | $858.01K |
| Costs And Expenses | $12.46M |
| Operating Expenses | $11.62M |
| Selling, General, and Administrative Expenses | $8.92M |
| Research and Development | $2.70M |
| Operating Income/Loss | -$11.11M |
| Income/Loss From Continuing Operations After Tax | -$11.13M |
| Income/Loss From Continuing Operations Before Tax | -$13.21M |
| Net Income/Loss | -$10.99M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$10.99M |
| Net Income/Loss Available To Common Stockholders, Basic | -$10.99M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.71 |
| Diluted Earnings Per Share | -$0.71 |
| Basic Average Shares | 43,203,453 |
| Diluted Average Shares | 43,203,453 |
| Assets | $22.37M |
| Current Assets | $16.69M |
| Prepaid Expenses | $835.42K |
| Other Current Assets | $15.85M |
| Noncurrent Assets | $5.68M |
| Fixed Assets | $1.42M |
| Other Non-current Assets | $4.26M |
| Liabilities | $22.93M |
| Current Liabilities | $16.92M |
| Accounts Payable | $762.91K |
| Other Current Liabilities | $16.16M |
| Noncurrent Liabilities | $6.01M |
| Equity | -$560.10K |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$560.10K |
| Liabilities And Equity | $22.37M |
| Net Cash Flow From Operating Activities | -$11.29M |
| Net Cash Flow From Operating Activities, Continuing | -$11.30M |
| Net Cash Flow From Investing Activities | -$461.93K |
| Net Cash Flow From Investing Activities, Continuing | -$461.93K |
| Net Cash Flow From Financing Activities | $19.31M |
| Net Cash Flow From Financing Activities, Continuing | $19.31M |
| Exchange Gains/Losses | $27.97K |
| Net Cash Flow | $7.58M |
| Net Cash Flow, Continuing | $7.54M |
| Comprehensive Income/Loss | -$10.96M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$10.96M |
| Other Comprehensive Income/Loss | -$10.96M |